Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CDX-014 in Advanced RCC and OCCC
NCT02837991Phase 1Terminated
- Sponsor
- Celldex Therapeutics
- Start
- Jun 2016
- Primary completion
- Nov 2018
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of CDX-014 in renal cell carcinoma (RCC) and ovarian clear cell carcinoma (OCCC), sponsored by Celldex Therapeutics. Primary endpoints: Maximum Tolerated Dose at 21 days and Objective Response Rate up to 5 years. Started Jun 2016; status: terminated.
02
Drugs
CDX-014
03
Conditions
renal cell carcinoma (RCC)ovarian clear cell carcinoma (OCCC)
Beyond the preview
Go deeper on NCT02837991.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02837991.